{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T03:08:10Z","timestamp":1773198490387,"version":"3.50.1"},"reference-count":59,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T00:00:00Z","timestamp":1726704000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Centre of Postgraduate Medical Education","award":["501-1-142-21-24"],"award-info":[{"award-number":["501-1-142-21-24"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Objectives. Venous and arterial thromboembolism (VTE\/ATE) often coexist with onco-hematologic diagnosis. This study aimed to assess the time relationship between the diagnosis of VTE\/ATE and blood cancers. The second aim was to identify VTE\/ATE risk factors related to the type of hematology disease and cardiac history. Methods. A total of 1283 patients underwent cardio-oncology evaluation at the Institute of Hematology and Transfusion Medicine in Warsaw from March 2021 through March 2023 (2 years), and 101 (7.8%) cases were identified with VTE\/ATE. Results. ATE compared with VTE significantly occurred more often before the diagnosis and treatment of hematologic malignancy: 33\/47 (70.2%) vs. 15\/54 (27.8%), p &lt; 0.0001. The risk of a VTE episode is exceptionally high in the first months after the diagnosis of an onco-hematological disease and the initiation of anticancer treatment. The higher frequency of VTE was associated with acute myeloid leukemia (17 cases\/270 patients\/6.30%\/p = 0.055), acute lymphocytic leukemia (7 cases\/76 patients\/9.21%\/p = 0.025), and chronic myeloproliferative disease (7 cases\/48 patients\/14.58%\/p = 0.0003). Only the risk of VTE was significantly increased before (OR = 6.79; 95% CI: 1.85\u201324.95; p = 0.004) and after diagnosis of myeloproliferative disease (OR = 3.12; 95% CI: 1.06\u20139.16; p = 0.04). Conclusions. ATEs occur more often than VTE before a diagnosis of blood cancer. The risk of VTE is exceptionally high before and after diagnosis of chronic myeloproliferative disease.<\/jats:p>","DOI":"10.3390\/cancers16183196","type":"journal-article","created":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T08:12:27Z","timestamp":1726733547000},"page":"3196","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Time Relationship between the Occurrence of a Thromboembolic Event and the Diagnosis of Hematological Malignancies"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7203-5390","authenticated-orcid":false,"given":"Jaros\u0142aw","family":"K\u0119pski","sequence":"first","affiliation":[{"name":"Department of Cardio-Oncology, Centre of Postgraduate Medical Education, 01-813 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3075-1943","authenticated-orcid":false,"given":"Sebastian","family":"Szmit","sequence":"additional","affiliation":[{"name":"Department of Cardio-Oncology, Centre of Postgraduate Medical Education, 01-813 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ewa","family":"Lech-Mara\u0144da","sequence":"additional","affiliation":[{"name":"Department of Hematology, Institute of Hematology and Transfusion Medicine, 02-776 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,9,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.thromres.2018.02.151","article-title":"Real-World Incidence of Cancer Following a First Unprovoked Venous Thrombosis: Results from the EPIGETBO Study","volume":"164","author":"Delluc","year":"2018","journal-title":"Thromb. Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1001\/archinte.165.15.1782","article-title":"Incidence of Venous Thromboembolism in the Year Before the Diagnosis of Cancer in 528 693 Adults","volume":"165","author":"White","year":"2005","journal-title":"Arch. Intern. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/j.1538-7836.2008.03268.x","article-title":"The Long-Term Risk of Cancer in Patients with a First Episode of Venous Thromboembolism","volume":"7","author":"Douketis","year":"2009","journal-title":"J. Thromb. Haemost."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jstrokecerebrovasdis.2008.01.007","article-title":"First-Ever Stroke as Initial Presentation of Systemic Cancer","volume":"17","author":"Taccone","year":"2008","journal-title":"J. Stroke Cerebrovasc. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1159\/000484668","article-title":"When to Screen Ischaemic Stroke Patients for Cancer","volume":"45","author":"Selvik","year":"2018","journal-title":"Cerebrovasc. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s11060-017-2741-0","article-title":"Predictors of Unknown Cancer in Patients with Ischemic Stroke","volume":"137","author":"Quintas","year":"2018","journal-title":"J. Neurooncol."},{"key":"ref_7","first-page":"CD010837","article-title":"Effect of Testing for Cancer on Cancer- and Venous Thromboembolism (VTE)-Related Mortality and Morbidity in People with Unprovoked VTE","volume":"8","author":"Robertson","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s13167-024-00354-8","article-title":"Cancer Screening in Hospitalized Ischemic Stroke Patients: A Multicenter Study Focused on Multiparametric Analysis to Improve Management of Occult Cancers","volume":"15","author":"Fang","year":"2024","journal-title":"EPMA J."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.acvd.2023.11.007","article-title":"Cancer-Related Arterial Thromboembolic Events","volume":"117","author":"Pernod","year":"2024","journal-title":"Arch. Cardiovasc. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e2317945","DOI":"10.1001\/jamanetworkopen.2023.17945","article-title":"Epidemiology of Cancer-Associated Venous Thromboembolism in Patients With Solid and Hematologic Neoplasms in the Veterans Affairs Health Care System","volume":"6","author":"Martens","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1002\/ijc.30280","article-title":"Systematic Review and Meta-analysis of the Risk of Severe and Life-threatening Thromboembolism in Cancer Patients Receiving anti-EGFR Monoclonal Antibodies (Cetuximab or Panitumumab)","volume":"139","author":"Miroddi","year":"2016","journal-title":"Int. J. Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2932","DOI":"10.1093\/annonc\/mdx514","article-title":"Meta-Analysis of Individual Patient Safety Data from Six Randomized, Placebo-Controlled Trials with the Antiangiogenic VEGFR2-Binding Monoclonal Antibody Ramucirumab","volume":"28","author":"Arnold","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/14740338.2017.1261824","article-title":"Risk of Arterial and Venous Occlusive Events in Chronic Myeloid Leukemia Patients Treated with New Generation BCR-ABL Tyrosine Kinase Inhibitors: A Systematic Review and Meta-Analysis","volume":"16","author":"Haguet","year":"2017","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1161\/ATVBAHA.120.314378","article-title":"Cancer Therapy\u2013Associated Thrombosis","volume":"41","author":"Grover","year":"2021","journal-title":"ATVB"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/eurheartj\/ehab674","article-title":"Defining Cardiovascular Toxicities of Cancer Therapies: An International Cardio-Oncology Society (IC-OS) Consensus Statement","volume":"43","author":"Herrmann","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"100739","DOI":"10.1016\/j.lanepe.2023.100739","article-title":"Impact of Venous Thromboembolism on the Mortality in Patients with Cancer: A Population-Based Cohort Study","volume":"34","author":"Pedersen","year":"2023","journal-title":"Lancet Reg. Health Eur."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jaccao.2021.02.007","article-title":"Arterial Thromboembolism in Cancer Patients: A Danish Population-Based Cohort Study","volume":"3","author":"Mulder","year":"2021","journal-title":"JACC CardioOncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"4721","DOI":"10.1182\/bloodadvances.2022008644","article-title":"The Prevalence of Thrombocytopenia in Patients with Acute Cancer-Associated Thrombosis","volume":"7","author":"Hsu","year":"2023","journal-title":"Blood Adv."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"101353","DOI":"10.1016\/j.beha.2022.101353","article-title":"Thrombosis and Bleeding in Hematological Malignancy","volume":"35","author":"Wang","year":"2022","journal-title":"Best. Pract. Res. Clin. Haematol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1111\/jth.15461","article-title":"Clinical Characteristics and Outcomes of Incidental Venous Thromboembolism in Cancer Patients: Insights from the Caravaggio Study","volume":"19","author":"Giustozzi","year":"2021","journal-title":"J. Thromb. Haemost."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.jacc.2017.06.047","article-title":"Risk of Arterial Thromboembolism in Patients With Cancer","volume":"70","author":"Navi","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1055\/s-0040-1712098","article-title":"Direct Oral Anticoagulants for the Treatment of Acute Venous Thromboembolism Associated with Cancer: A Systematic Review and Meta-Analysis","volume":"120","author":"Giustozzi","year":"2020","journal-title":"Thromb. Haemost."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e750","DOI":"10.1097\/HS9.0000000000000750","article-title":"EHA Guidelines on Management of Antithrombotic Treatments in Thrombocytopenic Patients With Cancer","volume":"6","author":"Falanga","year":"2022","journal-title":"HemaSphere"},{"key":"ref_24","first-page":"577","article-title":"Risk Factors Detection in Chronic Thromboembolic Pulmonary Hypertension, a Tool for Risk Quantification?","volume":"117","author":"Bohacekova","year":"2016","journal-title":"Bratisl. Lek\u00e1rske Listy"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1164\/rccm.202210-1941OC","article-title":"Clinical Phenotype and Outcomes of Pulmonary Hypertension Associated with Myeloproliferative Neoplasms: A Population-Based Study","volume":"208","author":"Montani","year":"2023","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/ejh.13543","article-title":"Prevalence and Risk Factors for Pulmonary Hypertension Associated with Chronic Myeloproliferative Neoplasms","volume":"106","author":"Ferrari","year":"2021","journal-title":"Eur. J. Haematol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","article-title":"2022 ESC\/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension","volume":"43","author":"Humbert","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.annonc.2022.12.014","article-title":"Venous Thromboembolism in Cancer Patients: ESMO Clinical Practice Guideline","volume":"34","author":"Falanga","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.23.00294","article-title":"Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Guideline Update","volume":"41","author":"Key","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1002\/ajh.25603","article-title":"Predicting Venous Thromboembolism in Multiple Myeloma: Development and Validation of the IMPEDE VTE Score","volume":"94","author":"Sanfilippo","year":"2019","journal-title":"Am. J Hematol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","article-title":"Development and Validation of a Predictive Model for Chemotherapy-Associated Thrombosis","volume":"111","author":"Khorana","year":"2008","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1056\/NEJMoa1814630","article-title":"Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer","volume":"380","author":"Khorana","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1814468","article-title":"Apixaban to Prevent Venous Thromboembolism in Patients with Cancer","volume":"380","author":"Carrier","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Paterno, G., Palmieri, R., Forte, V., Del Prete, V., Gurnari, C., Guarnera, L., Mallegni, F., Pascale, M.R., Buzzatti, E., and Mezzanotte, V. (2022). Predictors of Early Thrombotic Events in Adult Patients with Acute Myeloid Leukemia: A Real-World Experience. Cancers, 14.","DOI":"10.3390\/cancers14225640"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1634\/theoncologist.2013-0226","article-title":"Venous Thromboembolism Risk in Patients With Cancer Receiving Chemotherapy: A Real-World Analysis","volume":"18","author":"Lyman","year":"2013","journal-title":"Oncologist"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1182\/blood-2016-02-701094","article-title":"Disseminated Intravascular Coagulation at Diagnosis Is a Strong Predictor for Thrombosis in Acute Myeloid Leukemia","volume":"128","author":"Libourel","year":"2016","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.thromres.2009.12.023","article-title":"Venous Thromboembolism and Prognosis in Cancer","volume":"125","author":"Khorana","year":"2010","journal-title":"Thromb. Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.1182\/blood-2008-08-175745","article-title":"Venous Thromboembolism in Patients with Acute Leukemia: Incidence, Risk Factors, and Effect on Survival","volume":"113","author":"Ku","year":"2009","journal-title":"Blood"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"100155","DOI":"10.1016\/j.tru.2023.100155","article-title":"Risk Factors and Mortality Associated with Venous Thromboembolism in the Elderly US Population with Acute Lymphocytic Leukemia","volume":"14","author":"Faiz","year":"2024","journal-title":"Thromb. Update"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jamainternmed.2013.122","article-title":"Use of Glucocorticoids and Risk of Venous Thromboembolism: A Nationwide Population-Based Case-Control Study","volume":"173","author":"Johannesdottir","year":"2013","journal-title":"JAMA Intern. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1111\/bjh.17388","article-title":"Glucocorticoid Use and Risk of First and Recurrent Venous Thromboembolism: Self-controlled Case-series and Cohort Study","volume":"193","author":"Orsi","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer","volume":"382","author":"Agnelli","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on Cardio-Oncology Developed in Collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1055\/s-0040-1709527","article-title":"Variation in the Association between Antineoplastic Therapies and Venous Thromboembolism in Patients with Active Cancer","volume":"120","author":"Giustozzi","year":"2020","journal-title":"Thromb. Haemost."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41569-020-0347-2","article-title":"Vascular Toxic Effects of Cancer Therapies","volume":"17","author":"Herrmann","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ejca.2022.01.023","article-title":"Recurrent Venous Thromboembolism and Major Bleeding in Patients with Localised, Locally Advanced or Metastatic Cancer: An Analysis of the Caravaggio Study","volume":"165","author":"Verso","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jaccao.2023.01.009","article-title":"Tumor Genomic Profile Is Associated With Arterial Thromboembolism Risk in Patients With Solid Cancer","volume":"5","author":"Feldman","year":"2023","journal-title":"JACC CardioOncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1182\/blood.2020007878","article-title":"Incidence, Risk Factors, and Outcomes of Venous and Arterial Thromboembolism in Immune Checkpoint Inhibitor Therapy","volume":"137","author":"Moik","year":"2021","journal-title":"Blood"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1182\/blood.2020007338","article-title":"Venous Thromboembolism in Cancer Patients: A Population-Based Cohort Study","volume":"137","author":"Mulder","year":"2021","journal-title":"Blood"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.mayocp.2020.05.045","article-title":"Incidence and Risk of Various Types of Arterial Thromboembolism in Patients With Cancer","volume":"96","author":"Wang","year":"2021","journal-title":"Mayo Clin. Proc."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e013754","DOI":"10.1161\/JAHA.119.013754","article-title":"Reverse Cardio-Oncology: Cancer Development in Patients With Cardiovascular Disease","volume":"9","author":"Aboumsallem","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"102389","DOI":"10.1016\/j.cpcardiol.2024.102389","article-title":"Evolving Perspectives in Reverse Cardio-Oncology: A Review of Current Status, Pathophysiological Insights, and Future Directives","volume":"49","author":"Imran","year":"2024","journal-title":"Curr. Probl. Cardiol."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Liang, Z., He, Y., and Hu, X. (2022). Cardio-Oncology: Mechanisms, Drug Combinations, and Reverse Cardio-Oncology. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms231810617"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Sinha, A., Bavishi, A., Hibler, E.A., Yang, E.H., Parashar, S., Okwuosa, T., DeCara, J.M., Brown, S.-A., Guha, A., and Sadler, D. (2022). Interconnected Clinical and Social Risk Factors in Breast Cancer and Heart Failure. Front. Cardiovasc. Med., 9.","DOI":"10.3389\/fcvm.2022.847975"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ijcard.2022.06.048","article-title":"Potential Pathophysiologic Mechanisms Underlying the Inherent Risk of Cancer in Patients with Atherosclerotic Cardiovascular Disease","volume":"363","author":"Cianfrocca","year":"2022","journal-title":"Int. J. Cardiol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.yjmcc.2021.09.008","article-title":"Reverse Cardio-Oncology: Exploring the Effects of Cardiovascular Disease on Cancer Pathogenesis","volume":"163","author":"Koelwyn","year":"2022","journal-title":"J. Mol. Cell Cardiol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1161\/CIRCULATIONAHA.120.053315","article-title":"From Studying Heart Disease and Cancer Simultaneously to Reverse Cardio-Oncology","volume":"144","year":"2021","journal-title":"Circulation"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/ejhf.1920","article-title":"Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: A position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society","volume":"22","author":"Lyon","year":"2020","journal-title":"Eur. J. Heart Fail."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/18\/3196\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:59:26Z","timestamp":1760111966000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/18\/3196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,19]]},"references-count":59,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["cancers16183196"],"URL":"https:\/\/doi.org\/10.3390\/cancers16183196","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,19]]}}}